Talking Euretina

A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches

Three former mentees of the EURETINA Mentorship Programme share how the initiative helped shape their careers in retinal research and clinical practice. Özge Yanık Odabaş, Karolina Motloch and Omer Trivizki discuss mentorship, international collaboration, and the opportunities created through the programme’s growing alumni network. Their experiences highlight how structured mentorship can accelerate professional development for the next generation of retina specialists

Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future

Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Professor Aude Couturier, Professor Edoardo Midena, and Professor Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema

What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker (CEO, Eyepoint), Sascha Fauser (SVP, Roche), and Marion Munk (CSO, Gutblick Group; CMO, Isarna Therapeutics) about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics